StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Cancidas (caspofungin, legacy) by Quarter

Cancidas (caspofungin, legacy) — U.S. reported growth YoY (%) (%)

QuarterlyAnnual

Merck Cancidas (caspofungin, legacy): 81.0% in Q3 2022, up 100.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, Q3 2022
81.0%
Period ended Sep 30, 2022
Change on a year earlier
+100.0 pts
-19.0% in Q3 2021
History
15 quarters
Since Q4 2017
Sources
15
Documents cited below

Where the Q3 2022 figure comes from

“|| Cancidas | 43 | 56 | -24 | 1 | 1 | 81 | 42 | 56 | -25”

Source: Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗

Reported in Form 8-K Table 3a / 3b Product Sales.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCancidas (caspofungin, legacy) — U.S. reported growth YoY (%) (%)Year on yearSource
Q3 2022Sep 30, 202281.0%+100.0 ptsForm 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q1 2022Mar 31, 2022-47.0%-43.0 ptsForm 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q3 2021Sep 30, 2021-19.0%-99.0 ptsForm 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗
Q1 2021Mar 31, 2021-4.0%-137.0 ptsForm 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q3 2020Sep 30, 202080.0%–Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 2020-164.0%-140.0 ptsForm 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 2020133.0%+199.0 ptsForm 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q4 2019Dec 31, 2019-21.0%+12.0 ptsForm 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q2 2019Jun 30, 2019-24.0%+12.0 ptsForm 8-K (a19-15283_1ex99d1.htm, filed 2019-07-30) ↗
Q1 2019Mar 31, 2019-66.0%-33.0 ptsForm 8-K (a19-8996_1ex99d1.htm, filed 2019-04-30) ↗
Q4 2018Dec 31, 2018-33.0%+15.0 ptsForm 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2018Sep 30, 2018-62.0%–Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗
Q2 2018Jun 30, 2018-36.0%–Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗
Q1 2018Mar 31, 2018-33.0%–Form 8-K (a18-12417_1ex99d1.htm, filed 2018-05-01) ↗
Q4 2017Dec 31, 2017-48.0%–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Cite this data

StockData. (2026). Merck Cancidas (caspofungin, legacy) (%), quarterly Q4 2017–Q3 2022 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-cancidas-us-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.